It is one of the landmark patent cases in India. Novartis has been fighting to get a patent on Glivec since 2006. The Indian Patent Office had rejected its patent application based on the Amended Patent Acts of 2005.
At the heart of this case is Section 3(d), which was included in the Indian Patents Act in 2005. It denies patent to any new form of an already known substance or an already known compound unless it shows substantially enhanced efficacy.
Now, lawyers argue that Glivec, which is a beta crystalline form of an already known compound imatinib, is not patented under Section 3(D) of the Indian Patents Act. Section 3(D) was included in 2005 to avoid evergreening and to prevent an evergreening of patents by innovator firms by minor tweaks to the compound and to delay entry of generic products.
However, Novartis on its part argues that Glivec has shown 30 percent enhanced efficacy as against the original compound, which is imatinib. It is patented in 40 other countries. It is only India, which is not granted a patent to Glivec. The company says it is an invention and hence it should be given a patent under the Indian Patents Act too.
The other bone of contention is price. Glivec is costing over a lakh rupees for a month dosage while its other generic versions are available at one-tenth the cost.
Anda sedang membaca artikel tentang
Novartis cancer drug patent case verdict on April 1
Dengan url
http://untukkesehatanda.blogspot.com/2013/03/novartis-cancer-drug-patent-case.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Novartis cancer drug patent case verdict on April 1
namun jangan lupa untuk meletakkan link
Novartis cancer drug patent case verdict on April 1
sebagai sumbernya
0 komentar:
Posting Komentar